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S168 Oral Presentations3 adeno patients had detectable hexon-specific response (11 SFC/
110e5 cells), however, none of the 5 CMV+ patients had any
detectable SFC. However, after 9-12 days of stimulation we could
enumerate CTLp in 7/8 patients. For adenovirus, the median
hexon-specific response was 52 SFC/110e5 SFC (range 20-90),
and the penton-specific CTLp frequency was 13 SFC/110e5
(1 – 25). The median CMV pp65-specific response was 6.7 SFC/
110e5 (0-14).No responses were recorded against CMVEI-1 dem-
onstrating the critical role of antigenic restimulation by the
Ad5f35pp65 construct lacking IE. Smilarly in the adeno+/CMV-
patients we detected SFC solely against hexon and/or penton. All
patients are surviving at a median of 220 days after transplant (range
81-532).
Conclusion: To our knowledge these are the first data demonstrat-
ing that dormant virus-specific CTLp are present already in the first
2-3 months in most adenovirus or CMV infected UCBT recipients
(7/8 in this dataset). Although these rare events are below detection
by standard ELISPOT the feasibility of their ex vivo expansion may
lead to adoptive therapies.GVH/GVL
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COMMON COLD VIRUSES EARLY AFTER HSCT ARE ASSOCIATED WITH
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In lung transplantation, early infection (\100 d) with a common
respiratory virus (RV) is associated with acute or chronic rejection,
presenting as Bronchiolitis Obliterans (BO). After hematopoietic
stem cell transplantation (HSCT) alloimmune lung syndromes
(allo-LS), including Idiopathic Pneumonia Syndrome (IPS; acute)
and BO (chronic), also occur, but the role of RV is unclear. In
this prospective cohort study we analyzed the influence of common
RV early (\ 100 days) after HSCT, on the development of allo-LS
and survival. 110 paediatric patients with a median age of 5 years (2
mths – 21years), were included. They received a transplant (56
matched, 54 mismatched; 33 cord blood, 77 bone marrow; 33 fam-
ily, 77 unrelated) for malignant (56) and non-malignant (54) dis-
ease, after a TBI (33) or chemotherapy based (77) conditioning
regimen. In 50% of patients a RV infection occurred, at a median
of day +16 (range -7 to 100). RV was proven by qPCR on nasopha-
ryngeal aspirate: Rhinovirus was found most frequent (28), fol-
lowed by Parainfluenzavirus1-3, Coronavirus, Influenza A virus
and Adenovirus. Clinical symptoms were mild, and all patients re-
covered spontaneously, despite the fact that the RV remained pres-
ent for months in all patients. After a period without symptoms of
at least 2 weeks, new respiratory symptoms occurred in about 50%
of the RV positive patients. Based on additional examinations
including negative cultures (other than RV), radiology and pulmo-
nary function tests, 30 patients (27.2%) were diagnosed with allo-
LS: 18 IPS (16.4%) and 12 BO (10.9%), after a median time of 8
weeks (2-26). Multivariable analysis showed that RV infection is
an important predictor for allo-LS (p\0.0001). There was no
difference between Rhinovirus versus all others. Acute Graft-
versus-Host Disease (aGVHD), occurring at a median of 4 weeks
(2-15), had a protective effect on the development of allo-LS
(p5 0.004), most likely due to higher and prolonged immunesup-
pression in these patients. Overall survival was 73%; in the allo-LS
group this was only 53%. In multivariable analysis allo-LS was the
only predictor for mortality (p5 0.04).
In conclusion, early presence of RV is a predictor for the develop-
ment of allo-LS.We hypothesise that infection with a common cold
virus makes the lung a target for alloimmunity, leading to life threat-
ening lung disease. Paradoxically, prolonged immune suppression,
despite the local viral infection, protected against the development
of allo-LS.37
RAPID RECONSTITUTION OF THE REGULATORY T CELL COMPARTMENT
AFTER HIGH DOSE CYCLOPHOSPHAMIDE IMMUNOSUPPRESSION PRE-
VENTS THE DEVELOPMENT OF GVHD AFTER ALLOGENEIC BMT
Hess, A.D., Fuchs, E.J., Luznik, L., Thoburn, C.J., Kos, F., Jones, R.J.
The Johns Hopkins University, Baltimore, MD
Graft-versus-host disease (GVHD) is a life-threatening complica-
tion of allogeneic bone marrow transplantation (BMT). Although
the development of immunosuppressive regimens has reduced the
incidence and severity of this post transplant complication, GVHD
continues to be a significant clinical problem. There is also signifi-
cant toxicity associated with the multi-agent immunosuppressive
regimens. Recent studies revealed that high dose cyclophosphamide
(Cy, 50 mg/kg) was effective at reducing the incidence of grades
II-IV GVHD when administered as a single agent on days 3 and 4
following HLAmatched related and unrelated BMT. The incidence
of chronic GVHD was also reduced to 10%. The present studies
evaluated the reconstitution of the CD4 +CD25 + Foxp3+ regula-
tory T cell compartment in patients treated with single agent high
dose Cy. Peripheral blood lymphocytes (50 patients) were harvested
on days 30, 45 and 60 post transplant and evaluated for Foxp3, IL-2
and IFN-g mRNA transcript levels by real time PCR and by enu-
meration of CD4 +CD25 + Foxp3 + T cells by flow cytometry.
The results reveal that there was an inverse correlation of Foxp3
mRNA transcripts with the incidence of grades II-IVGVHD.Levels
of Foxp3 mRNA transcripts in patients who did not develop GVHD
were .100 fold greater than the levels detected in patients who de-
veloped GVHD. Interestingly, mRNA transcript levels of IL-2 and
IFN-g were significantly increased (.100-1000 fold) in patients
developing acute GVHD. Additional studies revealed that CD4 +
CD25 + Foxp3 + T cells enumerated flow cytometrically in a subset
of patients (16) were also detected at significant levels (30-50 cells/
ul) as early as day 30 in patients who did not develop GVHD. Com-
paratively, the number of CD4 +CD25 + Foxp3 + T cells in patients
who developed acute GVHD was\10 cells/ul and remained persis-
tently low even at day 60. The peripheral blood mononuclear cells
were also assessed for T cell recombinant excision circles (TRECs)
as a marker for recent thymic emigrants. Surprisingly, TRECs
were not detected at day 30. Taken together, these results suggest
that there is a rapid recovery of CD4 +CD25 + Foxp3+ regulatory
T cells in the majority of patients treated with high dose Cy which
may prevent the development of GVHD. The absence of TRECs
in these patients may suggest that the expansion of the regulatory
compartment may be antigen driven from amature T cell population
or expanded by homeostatic mechanisms.38
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Introduction:Despite the inadequacy of currentGvHDprophylaxis
for MHC-mismatched HSCT, the introduction of novel therapeu-
tics has been slow, likely due to the lack of a suitable translational
model to rigorously test emerging therapies.Herewedescribe anovel
Rhesusmacaquemodel,whichhas allowedus to evaluatemechanisms
controlling GvHD and its protection in a primate translational sys-
tem.
Methods: Using microsatellite-based MHC haplotyping, we devel-
oped the first MHC-defined primate HSCT system. HSCT recipi-
ents, prepared with 8 Gy TBI, received either no
immunosuppression or a costimulation blockade-based regimen
which included CD28 blockade (abatacept), CD40 blockade (with
the anti-CD40 antibody 3A8) and sirolimus after MHC haploident-
ical sibling HSCT. Recipients received a TNC dose of 9.3 +/-
2.7108/kg and a CD3+ cell dose of 1.1 +/- 0.88  108/kg.
Results: Three control recipients (no immunosuppression) demon-
strated rapid and complete donor engraftment, with T cell activation
and proliferation occurring by Day 7, coincident with the onset of
severe clinical GvHD. Flow cytometric analysis showed loss of
Oral Presentations S169CD127 expression on CD8 +T cells, consistent with their rapid
clonal expansion and differentiation. Multiplexed Luminex cytokine
analysis demonstrated high-level secretion of IL-18 and IL-1RA,
with no increased secretion of TNF, IL-1b or IL-17 despite severe
GvHD.
The four treated recipients demonstrated rapid donor engraft-
ment, but, unlike the controls, they were significantly protected
against clinical and immunologic GvHD: They displayed neither
the skin rash nor the profuse diarrhea noted in the control animals,
and flow cytometric analysis demonstrated control of T cell prolifer-
ation, maintenance of CD127 expression levels, and inhibition of
IL-18 and IL-1RA cytokine secretion.
Conclusions:We have established a robust model of MHC haploi-
dentical HSCT andGvHDusing anMHC-defined Rhesus macaque
colony.We find that unprotected primate GvHD is characterized by
rapid T cell proliferation, with concomitant loss of expression of
CD127 on CD8 +T cells. In addition, it is associated with high level
secretion of IL-18 and IL-1RA. Finally, we find that CD28/CD40-
directed costimulation blockade in combination with sirolimus can
effectively inhibit the clinical, cellular and serum hallmarks of
GvHD during primate haploidentical BMT. This approach thus
may deserve close scrutiny as a possible clinical strategy for GvHD
prevention.
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FEASIBILITY, SAFETY, EFFICACY AND IMMUNOLOGIC IMPACT OF DAILY
ULTRA-LOW-DOSE INTERLEUKIN-2 FOR STEROID-REFRACTORY
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Alyea, E.P.1, Cutler, C.1, Armand, P.1, Antin, J.H.1, Ritz, J.1,
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RegulatoryTcells (Treg) are deficient in chronic graft-versus-host-
disease (cGVHD). Interleukin-2 (IL-2) is critical in Treg develop-
ment, expansion and activity. We hypothesized daily subcutaneous
(SC) ultra-low-dose IL-2 (8 weeks on, 4 weeks off) may expandTregs
in steroid-refractory cGVHD. We report phase-I IL-2 outcomes at
dose-levels:A) 0.310^6 IU/m2 andB)110^6 IU/m2.Dose-level-C
accrual is ongoing. Concurrent immunosuppression was allowed.
11 patients accrued; 7 and 4 at dose-levels-A and -B. Median age
was 44 years (30-57). Median time from HSCT and cGVHD was
1021 (420-4714) and 784 (117-2233) days. cGVHD sites were skin
(11pts),mouth (6pts), eyes (4 pts), liver (3 pts), lung (2 pts), esophagus
(1 pt). Patients had amedian of 3 (range, 1-3) concurrent immunosup-
pressives: steroids (11 pts), sirolimus (5 pts), MMF (5 pts), tacrolimus
(4 pts). Discontinued prior therapies were rituximab (6 pts), ECP
(4 pts), MMF (2 pts), sirolimus (2 pts), cyclosporine (1 pt), thalido-
mide (1 pt), denileukin-diftitox (1 pt), alemtuzumab (1 pt).
No dose-limiting toxicity (DLT) GVHD flare occurred. One pa-
tient (lvl-A) had CTC grade-4 hemolytic-uremic-syndrome after
Hemophilus-B bacteremia at 5 weeks of IL-2 (and prednisone, tacro-
limus, sirolimus), reported as a DLT. No other DLT occurred. An-
other patient (lvl-A) hadCTCgrade-4MRSApneumonia at 8 weeks,
unrelated to IL-2 (on prednisone, sirolimus, MMF; also had MRSA
pneumonia pre-IL-2). No other significant infection was docu-
mented. One patient (lvl-B) discontinued IL-2 at 4 days for CTC
grade-1 fatigue.
Of 9 evaluable patients, 5 had a partial response, 1 had a mixed re-
sponse, and 3 had stable disease. Responses were scored in skin and
liver (mouth, eye received topical therapy). 4 of 5 responders chose
extended IL-2 (range, 1.5-15 months) given clinical benefit. The
5th, with resolving liver cGVHD, had IL-2 withheld for MRSA
pneumonia. He died of progressive liver cGVHD off IL-2.
IL-2 induced a 3-5-fold increase in CD4 +CD25 + CD127- Tregs
(Table). At 1, 2, 4, 6 and 8 weeks, IL-2 increased Treg significantly
over baseline (median difference5 17, 36, 60, 62, 59; p5 0.03, 0.04,
0.06, 0.05, 0.03, respectively). Similar changes were not seen in NK,
NK-T, or conventional T-cells.
We identify feasibility, safety, and efficacy of IL-2 in refractory
cGVHD. Treg expansion was marked despite steroid and calci-
neurin-inhibitor use. Ultra-low-dose SC IL-2 is a promising strategy
for cGVHD therapy and in-vivo Treg expansion.Table. Summary Statistics for CD41CD251CD127- T-reg-
ulatory Cells: Absolute Counts
Week N Median (range) cells/mLTreg Pre 9 17.3 (1.7, 41.8)
1 8 26.3 (14.3, 97.5)
2 10 50.2 (5.7, 400.9)
4 7 87.5 (22.2, 227.0)
6 9 67.7 (7.4, 188.5)
8 7 52.5 (22.3, 235.6)12 7 32.2 (10.6, 47.3)On IL-2: Week 1-8; Off IL-2: Week 8-12.40
ALLOGENEIC HUMAN MESENCHYMAL STEM CELL THERAPY (PROCHY-
MAL) AS A RESCUE AGENT FOR SEVERE TREATMENT RESISTANT
GVHD IN PEDIATRIC PATIENTS
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Severe acute graft vs. host disease (GVHD) unresponsive to ste-
roid and other immunosuppressive therapy typically leads to poor
outcomes and high mortality. Case reports of human mesenchymal
stem cells (MSCs) used for the rescue of pediatric patients with
severe GVHD resistant to multiple second line agents has generated
interest in the therapy because of its potential efficacy and encourag-
ing safety profile. In this study we evaluate the risk/benefit profile of
MSCs (Prochymal) administered under an FDA Expanded Access
Program (Protocol 275) as a rescue agent for treatment resistant
GVHD in pediatric patients.
Methods: Children with Grade B-D aGVHD failing steroids and
other agents were eligible for enrollment. Patients were given 8 bi-
weekly infusions of 2  106 cells/kg for 4 weeks, with an additional
4 infusions weekly after day 28 in patients with a partial response, de-
fined as improvement in at least one organ without progression in
others.
Results: 59 patients (median age of 8 years, 61% male, 55% Cauca-
sian, 83% recipient of an unrelated graft, and 41% cord blood) were
treated. At baseline, the distribution of aGVHD grades B:C:D was 6
(10%): 20 (33%): 33 (57%). Themedian duration of aGVHDbefore
enrollment was 29 days, and patients failed an average of 3.2 lines of
treatment for GVHD. Organ involvement was 60% skin, 87% gas-
trointestinal, and 38% liver. At day 28, overall response (OR), defined
as organ improvement of at least one stage without worsening in any
other,was 64%;17%of patients had stable disease ormixed response;
and 19% experienced progression. By grade, 28 day ORwas 67% for
B, 75% for C, and 58% for D. Response by organ was recorded, with
47% of skin, 23% of GI, and 39% of liver GVHD completely
responding (stage 0) within the first 28 days of treatment.Overall sur-
vival through study duration (day 100) was 62%. Achieving an OR at
day 28 resulted in a significantly higher probability of survival when
compared to patients who progressed within the first 28 days (76%
vs 9%, p\0.05). Prochymal was generally well tolerated and there
was no evidence of ectopic tissue formation.
Conclusion: Treatment with Prochymal produced a 64% response
rate in patients with otherwise refractory severe GVHD patients by
day 28. Response to Prochymal correlated with improved overall
survival at 100 days. MSC therapy appears to have an excellent
risk/benefit profile and should be considered in pediatric patients
with GVHD non-responsive to steroids.41
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